UY28182A1 - Uso de dipiridamol en combinación con ácido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular - Google Patents
Uso de dipiridamol en combinación con ácido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascularInfo
- Publication number
- UY28182A1 UY28182A1 UY28182A UY28182A UY28182A1 UY 28182 A1 UY28182 A1 UY 28182A1 UY 28182 A UY28182 A UY 28182A UY 28182 A UY28182 A UY 28182A UY 28182 A1 UY28182 A1 UY 28182A1
- Authority
- UY
- Uruguay
- Prior art keywords
- antagonist
- combination
- acid
- angiotensin
- acetilsalicyl
- Prior art date
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title abstract 4
- 229940123413 Angiotensin II antagonist Drugs 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000006011 Stroke Diseases 0.000 abstract 4
- 229960002768 dipyridamole Drugs 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10306179A DE10306179A1 (de) | 2003-02-13 | 2003-02-13 | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
| EP03018212 | 2003-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY28182A1 true UY28182A1 (es) | 2004-09-30 |
Family
ID=32870338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY28182A UY28182A1 (es) | 2003-02-13 | 2004-02-10 | Uso de dipiridamol en combinación con ácido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US20040214802A1 (enExample) |
| EP (2) | EP1733729A1 (enExample) |
| JP (1) | JP2006517557A (enExample) |
| KR (1) | KR20050100676A (enExample) |
| CN (1) | CN1750830A (enExample) |
| AR (1) | AR043173A1 (enExample) |
| AT (1) | ATE395921T1 (enExample) |
| AU (1) | AU2004212305A1 (enExample) |
| BR (1) | BRPI0407457A (enExample) |
| CA (1) | CA2515941A1 (enExample) |
| DE (2) | DE10306179A1 (enExample) |
| DK (1) | DK1603573T3 (enExample) |
| EA (1) | EA200501231A1 (enExample) |
| EC (1) | ECSP055963A (enExample) |
| ES (1) | ES2308147T3 (enExample) |
| HR (1) | HRP20050713A2 (enExample) |
| MX (1) | MXPA05008572A (enExample) |
| NO (1) | NO20054216L (enExample) |
| NZ (1) | NZ542302A (enExample) |
| PE (1) | PE20050191A1 (enExample) |
| PL (1) | PL378204A1 (enExample) |
| PT (1) | PT1603573E (enExample) |
| RS (1) | RS20050618A (enExample) |
| SI (1) | SI1603573T1 (enExample) |
| TW (1) | TW200501957A (enExample) |
| UA (1) | UA83481C2 (enExample) |
| UY (1) | UY28182A1 (enExample) |
| WO (1) | WO2004071385A2 (enExample) |
| ZA (1) | ZA200505956B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| DE10306179A1 (de) * | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
| CA2437709A1 (en) * | 2003-08-08 | 2005-02-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events |
| JP2005060359A (ja) * | 2003-08-13 | 2005-03-10 | Boehringer Ingelheim Pharma Gmbh & Co Kg | 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用 |
| WO2009080301A1 (en) * | 2007-12-21 | 2009-07-02 | Boehringer Ingelheim International Gmbh | Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke |
| WO2009100534A1 (en) * | 2008-02-14 | 2009-08-20 | Kardiatech, Inc. | Combination therapy to treat vascular disorders |
| US20100069326A1 (en) * | 2008-02-14 | 2010-03-18 | Wasimul Haque | Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders |
| WO2010097501A2 (en) * | 2009-02-26 | 2010-09-02 | Orion Corporation | A combination treatment |
| US8633158B1 (en) * | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
| WO2016119701A1 (en) | 2015-01-28 | 2016-08-04 | Realinn Life Science Limited | COMPOUNDS FOR ENHANCING PPARγ EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3031458A (en) * | 1958-02-05 | 1962-04-24 | Ciba Pharm Prod Inc | Isoindolines |
| US3031450A (en) | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
| US3317279A (en) * | 1963-03-15 | 1967-05-02 | Pennsalt Chemicals Corp | Polymorph of calcium disilicide and its method of preparation |
| JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
| DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| US4318477A (en) * | 1980-09-22 | 1982-03-09 | Kerpe Stase Z | Pharmaceutical package |
| DE3124090A1 (de) | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| DE3627423A1 (de) | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| CA1338238C (en) | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| US5015651A (en) | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| US4880804A (en) * | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
| SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| EP1013273A1 (en) | 1998-12-23 | 2000-06-28 | Novartis AG | Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| JP2002138054A (ja) * | 2000-08-25 | 2002-05-14 | Takeda Chem Ind Ltd | フィブリノーゲン低下剤 |
| JP2002293742A (ja) * | 2001-01-29 | 2002-10-09 | Takeda Chem Ind Ltd | 鎮痛・抗炎症剤 |
| JP2003212758A (ja) * | 2001-03-16 | 2003-07-30 | Takeda Chem Ind Ltd | 徐放性製剤の製造法 |
| DE10306179A1 (de) * | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
-
2003
- 2003-02-13 DE DE10306179A patent/DE10306179A1/de not_active Withdrawn
-
2004
- 2004-02-03 US US10/770,971 patent/US20040214802A1/en not_active Abandoned
- 2004-02-10 EA EA200501231A patent/EA200501231A1/ru unknown
- 2004-02-10 UY UY28182A patent/UY28182A1/es not_active Application Discontinuation
- 2004-02-10 AT AT04709596T patent/ATE395921T1/de not_active IP Right Cessation
- 2004-02-10 HR HR20050713A patent/HRP20050713A2/xx not_active Application Discontinuation
- 2004-02-10 EP EP06121998A patent/EP1733729A1/en not_active Withdrawn
- 2004-02-10 CN CNA2004800041078A patent/CN1750830A/zh active Pending
- 2004-02-10 CA CA002515941A patent/CA2515941A1/en not_active Abandoned
- 2004-02-10 JP JP2006501788A patent/JP2006517557A/ja active Pending
- 2004-02-10 PT PT04709596T patent/PT1603573E/pt unknown
- 2004-02-10 KR KR1020057014826A patent/KR20050100676A/ko not_active Withdrawn
- 2004-02-10 DE DE602004013937T patent/DE602004013937D1/de not_active Expired - Fee Related
- 2004-02-10 ES ES04709596T patent/ES2308147T3/es not_active Expired - Lifetime
- 2004-02-10 BR BR0407457-2A patent/BRPI0407457A/pt not_active IP Right Cessation
- 2004-02-10 US US10/544,239 patent/US20070004687A1/en not_active Abandoned
- 2004-02-10 MX MXPA05008572A patent/MXPA05008572A/es active IP Right Grant
- 2004-02-10 RS YUP-2005/0618A patent/RS20050618A/sr unknown
- 2004-02-10 AU AU2004212305A patent/AU2004212305A1/en not_active Abandoned
- 2004-02-10 SI SI200430789T patent/SI1603573T1/sl unknown
- 2004-02-10 NZ NZ542302A patent/NZ542302A/en unknown
- 2004-02-10 WO PCT/EP2004/001208 patent/WO2004071385A2/en not_active Ceased
- 2004-02-10 PL PL378204A patent/PL378204A1/pl not_active Application Discontinuation
- 2004-02-10 DK DK04709596T patent/DK1603573T3/da active
- 2004-02-10 EP EP04709596A patent/EP1603573B8/en not_active Expired - Lifetime
- 2004-02-11 PE PE2004000151A patent/PE20050191A1/es not_active Application Discontinuation
- 2004-02-12 TW TW093103344A patent/TW200501957A/zh unknown
- 2004-02-13 AR ARP040100446A patent/AR043173A1/es unknown
- 2004-10-02 UA UAA200508697A patent/UA83481C2/uk unknown
-
2005
- 2005-08-11 EC EC2005005963A patent/ECSP055963A/es unknown
- 2005-09-12 NO NO20054216A patent/NO20054216L/no not_active Application Discontinuation
-
2006
- 2006-02-09 ZA ZA200505956A patent/ZA200505956B/en unknown
- 2006-06-29 US US11/478,184 patent/US20060241089A1/en not_active Abandoned
-
2007
- 2007-12-18 US US11/958,499 patent/US20080113949A1/en not_active Abandoned
-
2008
- 2008-01-15 US US12/014,181 patent/US20080188497A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2003002731A1 (es) | Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe | |
| HN2005000795A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
| ECSP055525A (es) | Inhibidores de cinasas de tirosina | |
| CL2011000973A1 (es) | Compuestos derivados de pirazolo [1,5-a]pirimidina3-cabroxamida; composicion farmaceutica que los comprende, y uso para tratar o disminuir la gravedad de una enfermedad o condicion que responde a la inhibicion de la actividad de una jak quinasa. | |
| CR10091A (es) | Compuestos orgánicos | |
| CR10099A (es) | Inmunoglobulinas dirigidas contra nogo | |
| ECSP056132A (es) | Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis | |
| CL2007001178A1 (es) | Compuestos fusionados derivados de tetrahidro[1,2,4]triazol[4,3-a]pirimidina, moduladores de receptores de glutamato metabotropicos (mglur5); compuestos intermediarios; composicion y combinacion farmaceutica que los comprende; y su uso en la preparacion de medicamentos para tratar enfermedades gastroesofagicas, la ansiedad y dolores. | |
| CL2007002856A1 (es) | Compuestos derivados de pirazolo(1,5)pirimidina; composicion farmaceutica qu lo comprende;y su uso para tratar el cancer. | |
| ECSP056173A (es) | Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 | |
| CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. | |
| PA8803201A1 (es) | Derivados acidos de cicloalquilamino | |
| ECSP12007431A (es) | Compuestos orgánicos | |
| AR109263A2 (es) | Composición que comprende moxidectina | |
| GT200600135A (es) | Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales | |
| ECSP055963A (es) | Uso de dipiradamol en combinación con acido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular | |
| BRPI0519656A2 (pt) | terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida | |
| AR058173A1 (es) | Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas | |
| BRPI0511475A (pt) | combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer | |
| ECSP066805A (es) | Compuestos silinano como inhibidores de cisteína proteasa | |
| DE602004014787D1 (de) | Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln | |
| MX2007007610A (es) | Regimen de cladribina para tratar esclerosis multiple. | |
| AR106331A2 (es) | N-benzoil-estaurosporina, forma ii | |
| PE20030732A1 (es) | Empleo de alquilfosfocolinas en el tratamiento preventivo de enfermedades causadas por protozoarios | |
| BRPI0416906A (pt) | proteinúria tubular como um indicador para risco cardiovascular elevado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20140310 |